Genovis Investor Relations » Press Releases

February 14, 2025 08:00 (CET) Strong momentum: 21% growth in enzyme business and significant improvement in earnings Regulatory MAR

November 08, 2024 08:00 (CET) Genovis AB: Interim Report January-September 2024 Regulatory MAR

November 08, 2024 08:00 (CET) Interim Report January-September 2024 Regulatory MAR

September 23, 2024 15:00 (CEST) Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics Regulatory

August 20, 2024 08:00 (CEST) Half-Yearly Report January - June 2024 Regulatory MAR

August 19, 2024 19:00 (CEST) Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc. Regulatory MAR

July 04, 2024 14:45 (CEST) Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors Regulatory

May 15, 2024 18:54 (CEST) Communiqué from Genovis AB (publ) Annual General Meeting May 15, 2024 Regulatory

May 15, 2024 15:00 (CEST) Interim Report January – March 2024 Regulatory MAR

April 24, 2024 08:00 (CEST) Genovis Annual Report 2023 published Regulatory

Press Releases